For instance, in the underway NCT02997228 trial, 347 CRC patients will be treated in the first-line setting with either Atezolizumab or with the combination of the first-line chemotherapy regimen, FOLFOX, plus the VEGF antagonist, Bevacizumab, or with the combination of both treatments. Here, VEGFA is linked to colorectal carcinoma.